Non Small Cell Lung Cancer News and Research RSS Feed - Non Small Cell Lung Cancer News and Research

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer. [More]
Study: 1 in 4 patients with advanced lung cancer does not receive EGFR test results before treatment

Study: 1 in 4 patients with advanced lung cancer does not receive EGFR test results before treatment

Almost one in four patients (24%) with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment, researchers report at the European Lung Cancer Conference. [More]
Some lung cancer patients can benefit from melanoma drugs

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland. [More]
Itraconazole drug shows potential in cancer treatment

Itraconazole drug shows potential in cancer treatment

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience. [More]
Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Small cell lung cancer (SCLC) will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City. [More]
Two radiologists win Society of Interventional Radiology Foundation Leaders in Innovation Award

Two radiologists win Society of Interventional Radiology Foundation Leaders in Innovation Award

Two visionaries of interventional radiology were recently awarded the Society of Interventional Radiology Foundation Leaders in Innovation Award. The awards, to Lindsay Machan, M.D., FSIR, an interventional radiologist at Vancouver Hospital, British Columbia, and Kieran J. Murphy, M.D., FSIR, an interventional radiologist at the University of Toronto, both in Canada, were announced March 4 during the society's Annual Scientific Meeting in Atlanta. [More]
Study finds no strong link between lung cancer risk and reproductive history variables

Study finds no strong link between lung cancer risk and reproductive history variables

The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for a role of hormone use in the incidence of lung cancer. [More]
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao. [More]
Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors

Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. [More]
TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

TPU's submission of Docetaxel Injection Concentrate, Non-Alcohol Formula NDA acknowledged by FDA

Teikoku Pharma USA announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA. [More]
Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly, Innovent Biologics announce biotech drug development collaborations in China

Eli Lilly and Company and Innovent Biologics, Inc. today announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company. [More]
Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers. [More]
Patients who receive definitive CCRT treatment for stage III NSCLC have longer overall survival

Patients who receive definitive CCRT treatment for stage III NSCLC have longer overall survival

Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers. [More]
Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121. [More]
CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome. [More]
New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel. [More]
Facts about precision medicine

Facts about precision medicine

President Barack Obama is requesting an increase of $215 million in the 2016 federal budget to launch the Precision Medicine Initiative. This boost in funding for research will give genetic causes of cancer a national focus specifically around precision or "personalized" treatments for cancer in the future. [More]
CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees. [More]
Advertisement